BACKGROUNDIt has been proven that ezrin protein may interact with E-cadherin protein and take part in metastasis of tumors. The aim of this study is to detect the expression of ezrin and E-cadherin and their significance in non-small cell lung cancer (NSCLC) with tissue microarray technique.

METHODSEzrin and E-cadherin proteins were detected in 25 cases of benign pulmonary tissues, 287 cases of NSCLC tissues and 120 cases of metastatic lymph nodes by LSAB method of immunohistochemical staining. All patients were followed up.

RESULTSThe overexpression rate of ezrin in primary NSCLC tissues and metastatic lymph nodes was 57.8% and 83.3% respectively (P=0.000). The abnormal expression rate of E-cadherin in primary NSCLC tissues and metastatic lymph nodes was 82.6% and 98.3% respectively (P=0.000). The overexpression rate of ezrin was significantly related to grading (P=0.005) and metastasis (P=0.032). The abnormal expression rate of E-cadherin was closely related to grading (P=0.024), metastasis (P=0.015) and TNM stages (P=0.037). There was a negative correlation between expression of ezrin and E-cadherin (P=0.029). Grading, metastasis of NSCLC, TNM stages, overexpression of ezrin and abnormal expression of E-cadherin were independent prognostic factors of NSCLC (P < 0.05).

CONCLUSIONSOverexpression of ezrin and abnormal expression of E-cadherin may promote tumor metastasis. Ezrin and E-cadherin may be useful prognostic markers for patients with advanced NSCLC.

Since the outbreak of corona virus disease 2019(COVID 19), the epidemic has spread rapidly, which brings great challenge to the surgical diagnosis, treatment and management of lung neoplasm Sichuan International Medical Exchange &Promotion Association organized thoracic surgery experts to sum up experiences from experts in major hospital, and formulated the Guidance suggestion on surgical diagnosis, treatment and management of lung neoplasm during the outbreak of COVID-19 to provide references for thoracic surgeons.

BACKGROUND: The relationship between quality of life at three months after lung cancer surgery and different surgical approaches is remains unclear. This study aimed to compare the quality of life of patients three months after uniportal and multiportal thoracoscopic lobectomy. METHODS: Data from patients who underwent lung surgery at the Department of Thoracic Surgery, Sichuan Cancer Hospital between April 2021 and October 2021 were collected. The European Organization for Research and Treatment of Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and Quality of Life Questionnaire-Lung Cancer 29 (EORTC QLQ-LC29) were used to collect quality of life data of the patients. Potential confounding factors in the baseline data were included in a multivariate regression model for adjustment, and the quality of life of the two groups three months postoperatively was compared with traditional clinical outcomes. RESULTS: A total of 130 lung cancer patients were included, with 57 males (43.8%) and 73 females (56.2%), and an average age of (57.1±9.5) yr. In the baseline data of the two groups, there was a statistical difference in the number of chest drainage tubes placed (P<0.001). After adjustment with the regression model, at three months postoperatively, there were no significant differences in all symptoms and functional status scores between the two groups (all P>0.05). The multiportal group had longer surgery time (120.0 min vs 85.0 min, P=0.001), postoperative hospital stay (6.0 d vs 4.0 d, P=0.020), and a higher incidence of early ≥ grade 2 complications (39.0% vs 10.1%, P=0.011) compared to the uniportal group. CONCLUSIONS Patients undergoing uniportal and multiportal thoracoscopic lobectomy have similar quality of life at three months postoperatively. The uniportal group may have certain advantages in terms of traditional clinical outcome indicators such as operation time, postoperative hospital stay, and early postoperative complications.
Male ; Female ; Humans ; Lung Neoplasms/surgery* ; Quality of Life ; Thoracic Surgery, Video-Assisted/adverse effects* ; Pneumonectomy/adverse effects* ; Postoperative Complications/surgery* ; Retrospective Studies